Novartis: license agreement for immuno-dermatology compound

(CercleFinance.com) - Novartis has entered into an exclusive agreement with Belgium's Galapagos and Germany's MorphoSys by licensing their compound for atopic dermatitis.


Under the agreement, the Swiss biopharmaceutical group will acquire the exclusive global development and marketing rights to MOR106 for atopic dermatitis and all other potential indications.

Novartis will make an upfront payment of 95 million euros to Galapagos and MorphoSys, and additional payments, royalties and fees pending milestones.

Yeterday, Novartis announced a new approval for Kisqali from the US Food and Drug Administration (FDA) for women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.

Copyright (c) 2018 CercleFinance.com. All rights reserved.